Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Dopashydrazine tablets (medoba)

It is used to treat Parkinson's disease and symptomatic Parkinson's syndrome (post encephalitis, arteriosclerosis or toxic), but does not include drug-induced Parkinson's syndrome. More role
App download minus 10 yuan
Common name:
Dopashydrazine tablets
Product No.:
C14202006866
Approval No.:
Gyzz h10930198 (inquired by the State Drug Administration)
Jianke price:
¥99.00
Product specification:
0.25g*40s
Manufacturer:
Shanghai Roche Pharmaceuticals
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Dopashydrazine tablets (medoba)
Main raw materials This product is a compound preparation, and its components are: each tablet contains 200mg levodopa and 50mg benzylhydrazine (equivalent to 57mg benzylhydrazine hydrochloride).
Main role It is used to treat Parkinson's disease and symptomatic Parkinson's syndrome (post encephalitis, arteriosclerosis or toxic), but does not include drug-induced Parkinson's syndrome.
Product specification 0.25g*40s
Usage and dosage The most suitable daily dosage of this product must be determined according to the situation of different patients. The following dosage table can be used as a basic reference: 1. Initial treatment. The first recommended dosage of this product is 1 / 2 tablets each time, three times a day. After that, the daily dosage of each week will be increased by 1 / 2 tablets until the treatment amount suitable for the patient is reached. If the patient sees a doctor regularly, the dosage can be increased faster. For example, the daily dose can be increased twice a week and 1 / 2 medoba tablets can be added each time, so that the effective dose can be achieved quickly. The effective dose is usually between 2-4 tablets a day and taken 3-4 times a day. The daily dosage rarely requires more than 5 tablets. (see instructions for details)
manufacturing enterprise Shanghai Roche Pharmaceuticals
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Dopashydrazine tablets (medoba)

[common name] Dopashydrazine tablets

[specification and model] 0.25g*40s

[manufacturer] Shanghai Roche Pharmaceuticals

[drug type] Western medicine

[approval No.] Gyzz h10930198

[validity period] 48 months

[functional indications] It is used to treat Parkinson's disease and symptomatic Parkinson's syndrome (post encephalitis, arteriosclerosis or toxic), but does not include drug-induced Parkinson's syndrome.

[usage and dosage] The most suitable daily dosage of this product must be determined according to the situation of different patients. The following dosage table can be used as a basic reference: 1. Initial treatment. The first recommended dosage of this product is 1 / 2 tablets each time, three times a day. After that, the daily dosage of each week will be increased by 1 / 2 tablets until the treatment amount suitable for the patient is reached. If the patient sees a doctor regularly, the dosage can be increased faster. For example, the daily dose can be increased twice a week and 1 / 2 medoba tablets can be added each time, so that the effective dose can be achieved quickly. The effective dose is usually between 2-4 tablets a day and taken 3-4 times a day. The daily dosage rarely requires more than 5 tablets. (see instructions for details)

[adverse reactions] 1. Blood and lymphatic system: hemolytic anemia, transient leucopenia and thrombocytopenia are reported in very few cases. Therefore, in the long-term use of drugs containing levodopa, blood cells, liver and kidney functions should be checked regularly. 2. Metabolism and nutrition: anorexia is reported. 3. Mental symptoms: patients treated with medoba may have depression, but this may also be a clinical manifestation of patients with Parkinson's disease and hyperactive leg syndrome. Excitement, anxiety, insomnia, hallucinations, delusions and transient disorientation may occur in elderly patients or patients with similar medical history. 4. Nervous system: individual cases reported taste loss or taste disorder. In the later stage of treatment, there may be movement disorders (such as chorea like movement or hand foot ADHD), and reducing the dosage can usually eliminate or tolerate the symptoms. With the extension of treatment time, there may also be fluctuations in treatment response, including freezing attack, end-of-dose deterioration and & ldquo; On off & rdquo; Phenomenon, etc. It can usually be eliminated or tolerated by adjusting the dose or a small amount of multiple administration, and then the dose can be gradually increased to enhance the efficacy. Taking medoba is associated with drowsiness and, in rare cases, excessive daytime hypnosis or sudden sleep attacks. 5. Heart: occasional arrhythmia. 6. Blood vessels: orthostatic hypotension is occasionally seen. Reducing the dose of medoba usually improves orthostatic hypotension. 7. Gastrointestinal tract: nausea, vomiting and diarrhea were reported during medoba administration. Gastrointestinal adverse reactions mainly occur in the initial stage of treatment, which can be basically controlled by taking it with food or drink or slowly increasing the dose. (see the inner packaging manual for details)

[precautions] See the instructions for details.

[taboo] This product is forbidden to be used in patients who are known to be allergic to levodopa, benserihydrazine or their excipients. It is forbidden to use this product with non selective monoamine oxidase inhibitors, but selective monoamine oxidase B inhibitors (such as selegilan and resagilan) and selective monoamine oxidation a inhibitors (such as moclobemide) are not prohibited. The combination of monoamine oxidase A and monoamine oxidase B inhibitors is equivalent to non selective monoamine oxidase inhibitors, so they should not be used in combination with this product (see [drug interaction]). This product is forbidden in the decompensated period of the following diseases: endocrine diseases, renal function damage (except dialysis patients with restless legs syndrome), liver function damage or heart disease. It is forbidden for patients with mental diseases and angle closure glaucoma. (Note: This product has not been approved for restless legs syndrome in China) This product is forbidden for patients under the age of 25 (patients with complete bone development). This product is forbidden for pregnant women and women with potential pregnancy without effective contraceptive measures (see [medication for pregnant women and lactating women]). If the patient is pregnant during medication, the medication should be stopped (as recommended by the prescribing physician).

[listing Permit Holder] Shanghai Roche Pharmaceuticals

[packaging unit] box

[main ingredients] This product is a compound preparation, and its components are: each tablet contains 200mg levodopa and 50mg benzylhydrazine (equivalent to 57mg benzylhydrazine hydrochloride).

[character] This product is a colored film.

[applicable population] adult

[medication for pregnant and lactating women] Animal experiments show that this product may affect the bone development of embryos. Therefore, it is absolutely prohibited to be used in pregnancy or women who are not using effective contraceptives but have the possibility of pregnancy. Because it is unknown whether benserazid can enter the milk, mothers taking medoba are prohibited from breastfeeding, because the possibility of infant bone deformity cannot be ruled out.

[medication for children] Not suitable for use under 25 years of age.

[medication for elderly patients] Same usage and dosage.

[storage] Keep in a cool and dry place (no more than 20 ℃).

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Dopashydrazine tablets (medoba)

    ¥99.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!